Posted inBiotechnology
Posted inBiotechnology
Scribe records upsized $129M IPO to bankroll lipid-lowering genetic meds
In vivo gene editing outfit Scribe Therapeutics has priced its IPO at $128.7 million, surpassing the $96 million goal set…














